WallStSmart

DaVita HealthCare Partners Inc (DVA)vsMednax Inc (MD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

DaVita HealthCare Partners Inc generates 618% more annual revenue ($14.01B vs $1.95B). MD leads profitability with a 9.0% profit margin vs 6.0%. MD appears more attractively valued with a PEG of 0.24. DVA earns a higher WallStSmart Score of 70/100 (B).

DVA

Strong Buy

70

out of 100

Grade: B

Growth: 7.3Profit: 7.0Value: 7.3Quality: 5.5
Piotroski: 3/9Altman Z: 1.22

MD

Buy

63

out of 100

Grade: C+

Growth: 4.0Profit: 6.5Value: 9.3Quality: 5.5
Piotroski: 5/9Altman Z: 1.71
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

DVAOvervalued (-12.9%)

Margin of Safety

-12.9%

Fair Value

$127.80

Current Price

$183.72

$55.92 premium

UndervaluedFair: $127.80Overvalued
MDUndervalued (+65.0%)

Margin of Safety

+65.0%

Fair Value

$61.35

Current Price

$26.35

$35.00 discount

UndervaluedFair: $61.35Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DVA5 strengths · Avg: 9.6/10
PEG RatioValuation
0.4510/10

Growing faster than its price suggests

Return on EquityProfitability
81.0%10/10

Every $100 of equity generates 81 in profit

EPS GrowthGrowth
55.8%10/10

Earnings expanding 55.8% YoY

Debt/EquityHealth
-14.0910/10

Conservative balance sheet, low leverage

P/E RatioValuation
15.6x8/10

Attractively priced relative to earnings

MD3 strengths · Avg: 8.7/10
PEG RatioValuation
0.2410/10

Growing faster than its price suggests

P/E RatioValuation
12.9x8/10

Attractively priced relative to earnings

Price/BookValuation
2.4x8/10

Reasonable price relative to book value

Areas to Watch

DVA3 concerns · Avg: 2.7/10
Profit MarginProfitability
6.0%3/10

6.0% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Altman Z-ScoreHealth
1.222/10

Distress zone — elevated risk

MD2 concerns · Avg: 4.0/10
Revenue GrowthGrowth
4.0%4/10

4.0% revenue growth

Altman Z-ScoreHealth
1.714/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : DVA

The strongest argument for DVA centers on PEG Ratio, Return on Equity, EPS Growth. PEG of 0.45 suggests the stock is reasonably priced for its growth.

Bull Case : MD

The strongest argument for MD centers on PEG Ratio, P/E Ratio, Price/Book. PEG of 0.24 suggests the stock is reasonably priced for its growth.

Bear Case : DVA

The primary concerns for DVA are Profit Margin, Piotroski F-Score, Altman Z-Score.

Bear Case : MD

The primary concerns for MD are Revenue Growth, Altman Z-Score.

Key Dynamics to Monitor

DVA carries more volatility with a beta of 0.83 — expect wider price swings.

DVA is growing revenue faster at 5.2% — sustainability is the question.

DVA generates stronger free cash flow (320M), providing more financial flexibility.

Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

DVA scores higher overall (70/100 vs 63/100). MD offers better value entry with a 65.0% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

DaVita HealthCare Partners Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

DaVita Inc. provides kidney dialysis services through a network of outpatient dialysis centers in the United States.

Mednax Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

MEDNAX, Inc., provides neonatal, maternal-fetal, pediatric cardiology, and other pediatric subspecialties in the United States and Puerto Rico. The company is headquartered in Sunrise, Florida.

Visit Website →

Want to dig deeper into these stocks?